Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) had its target price decreased by BMO Capital Markets from $221.00 to $160.00 in a research note published on Friday morning. BMO Capital Markets currently has an outperform rating on the biopharmaceutical company’s stock.
ICPT has been the subject of several other reports. Cantor Fitzgerald restated an underweight rating and set a $69.00 price target (up from $60.00) on shares of Intercept Pharmaceuticals in a research note on Tuesday, August 8th. Oppenheimer Holdings, Inc. restated an outperform rating and set a $200.00 price target on shares of Intercept Pharmaceuticals in a research note on Thursday, September 14th. Jefferies Group LLC restated a buy rating and set a $275.00 price target on shares of Intercept Pharmaceuticals in a research note on Wednesday. Royal Bank Of Canada began coverage on Intercept Pharmaceuticals in a research note on Thursday, September 14th. They set an outperform rating and a $244.00 price target for the company. Finally, BidaskClub upgraded Intercept Pharmaceuticals from a hold rating to a buy rating in a research note on Friday, June 23rd. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Intercept Pharmaceuticals currently has a consensus rating of Hold and a consensus price target of $174.37.
Shares of Intercept Pharmaceuticals (NASDAQ ICPT) traded down 16.43% during mid-day trading on Friday, hitting $61.59. The company had a trading volume of 11,875,646 shares. Intercept Pharmaceuticals has a 12 month low of $60.97 and a 12 month high of $172.95. The company’s market cap is $1.55 billion. The firm has a 50-day moving average of $106.75 and a 200-day moving average of $115.74.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($3.62) by $0.16. The company had revenue of $30.89 million during the quarter, compared to analyst estimates of $27.50 million. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The firm’s revenue was up 459.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($3.14) earnings per share. On average, analysts expect that Intercept Pharmaceuticals will post ($13.91) EPS for the current year.
TRADEMARK VIOLATION WARNING: “Intercept Pharmaceuticals, Inc. (ICPT) Price Target Lowered to $160.00 at BMO Capital Markets” was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://stocknewstimes.com/2017/09/23/intercept-pharmaceuticals-inc-icpt-price-target-lowered-to-160-00-at-bmo-capital-markets.html.
In other Intercept Pharmaceuticals news, insider Lisa Bright sold 394 shares of the stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $121.33, for a total transaction of $47,804.02. Following the transaction, the insider now owns 23,619 shares of the company’s stock, valued at approximately $2,865,693.27. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Daniel G. Welch sold 217 shares of the stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $126.76, for a total value of $27,506.92. Following the transaction, the director now directly owns 3,710 shares in the company, valued at approximately $470,279.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 48,013 shares of company stock valued at $6,198,747. 9.20% of the stock is owned by insiders.
A number of large investors have recently added to or reduced their stakes in the business. WFG Advisors LP lifted its holdings in Intercept Pharmaceuticals by 16.4% during the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 125 shares during the last quarter. Dynamic Technology Lab Private Ltd lifted its holdings in Intercept Pharmaceuticals by 85.6% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 6,798 shares of the biopharmaceutical company’s stock worth $824,000 after buying an additional 3,136 shares during the last quarter. Public Employees Retirement System of Ohio lifted its holdings in Intercept Pharmaceuticals by 15.0% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 7,385 shares of the biopharmaceutical company’s stock worth $894,000 after buying an additional 965 shares during the last quarter. Asymmetry Capital Management L.P. bought a new position in Intercept Pharmaceuticals during the 2nd quarter worth approximately $3,580,000. Finally, Nomura Holdings Inc. bought a new position in Intercept Pharmaceuticals during the 2nd quarter worth approximately $366,000. 82.19% of the stock is currently owned by institutional investors.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.